Diffusion Pharmaceuticals (DFFN) Commences Phase 3 Clinical Trial with TSC in Glioblastoma Multiforme
Tweet Send to a Friend
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) today announced that a Phase 3 clinical trial using its lead small molecule trans sodium ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
